While Haemonetics Corp has underperformed by -1.69%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, HAE fell by -0.10%, with highs and lows ranging from $97.97 to $70.25, whereas the simple moving average jumped by 9.09% in the last 200 days.
On November 08, 2024, Raymond James Upgraded Haemonetics Corp (NYSE: HAE) to Strong Buy. A report published by CL King on September 13, 2024, Initiated its previous ‘Buy’ rating for HAE. BofA Securities also rated HAE shares as ‘Neutral’, setting a target price of $85 on the company’s shares in an initiating report dated September 11, 2024. BTIG Research Initiated an Buy rating on September 10, 2024, and assigned a price target of $112. Needham June 12, 2024d its ‘Hold’ rating to ‘Buy’ for HAE, as published in its report on June 12, 2024. Mizuho’s report from October 13, 2022 suggests a price prediction of $90 for HAE shares, giving the stock a ‘Buy’ rating. Needham also rated the stock as ‘Hold’.
Analysis of Haemonetics Corp (HAE)
Further, the quarter-over-quarter increase in sales is 8.59%, showing a positive trend in the upcoming months.
There are several well-rounded types of analysis and research techniques that can be used to gain a clear view of Haemonetics Corp’s future performance, with equity being one of the most critical indicators. The goal here is to ensure that your current return on equity of 13.97% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 2.09, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
As an indicator of volatility for any stock, average volume can also be very valuable, and HAE is recording an average volume of 611.59K. On a monthly basis, the volatility of the stock is set at 2.99%, whereas on a weekly basis, it is put at 3.46%, with a gain of 2.06% over the past seven days. Furthermore, long-term investors anticipate a median target price of $110.80, showing growth from the present price of $89.22, which can serve as yet another indication of whether HAE is worth investing in or should be passed over.
How Do You Analyze Haemonetics Corp Shares?
Haemonetics Corp (HAE) is based in the USA and is one of the most prominent companies operating in the Medical Instruments & Supplies market. When comparing Haemonetics Corp shares with other companies under Healthcare, the P/E value is an influential factor to note. This is because it represents an indication of the future growth of the company in terms of investors’ expectations. Ultimately, the value of the latter should demonstrate steady, rapid growth, which is an accurate measure of the company’s progress. In addition to the value of 37.05, there is a growth in quarterly earnings of 36.24%.
Apart from looking at the fundamentals, you should also pay attention to the number of company employees who own shares. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 1.10%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 112.12% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
HAE shares are owned by institutional investors to the tune of 112.12% at present.
